Table 8 Value (rNPV) after each phase (in millions of $)
From: Financing repurposed drugs for rare diseases: a case study of Unravel Biosciences
| Â | Distribution | Average | Standard deviation | Upper bound |
|---|---|---|---|---|
Discovery, preclinical development, and phase 1 | Log-normal | 23.2 | 21.5 | 120 |
Phase 2 | Log-normal | 117.1 | 96.3 | 330 |
Phase 3 | Log-normal | 292.3 | 240.5 | 690 |
FDA submission-to-launch | Log-normal | 406.5 | 289.1 | 880 |
Overall | Log-normal | 8.8 | 12.8 | 70 |